



November 25, 2014

Fate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference

SAN DIEGO, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company's programs at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2nd, 2014 at 12:10 pm EST in New York, NY.

A live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat severe, life-threatening diseases. The Company's approach utilizes established pharmacologic modalities, such as small molecules, and targets well-characterized biological mechanisms to program the fate and enhance the therapeutic potential of adult stem cells. The Company's lead product candidate, PROHEMA[®], is an *ex vivo* programmed hematopoietic stem cell, or HSC, therapeutic, which is currently in clinical development for patients undergoing HSC transplantation. The Company is also applying its reprogramming modulators to develop human induced pluripotent stem cell-derived cellular therapeutics, and evaluating the *in vivo* programming of muscle satellite stem cells using its Wnt7a-based protein analogs for muscle regeneration. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

CONTACT: Renee Leck, Stern Investor Relations, Inc.

212.362.1200, renee@sternir.com